Revance Office
COMPANY

About Revance

Revance is a biotechnology company setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings. Revance is an innovation leader in aesthetics and therapeutics.

COMPANY

About Revance

Revance is a biotechnology company setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings. Revance is an innovation leader in aesthetics and therapeutics.

More then one hundred years of experience

Revance’s deep experience commercializing products for large pharmaceutical companies in highly competitive markets represents more than one hundred years of experience launching innovative products that change people’s lives. Read More.

Revance’s headquarters is in Nashville, TN, while the company’s R&D and manufacturing hub is located in Newark, CA. Its technology hub is in Pleasanton, CA, and its commercial offices are in Irvine, CA.

CERTIFIED AUGUST 2021 – AUGUST 2022
Great Place to Work

Aesthetics

Building the Prestige Market

Revance Aesthetics is building a premium category in facial aesthetics, focused on differentiated and improved outcomes, a compelling value proposition and an elevated experience for physicians and patients. Our portfolio of expertly created products and services deliver a differentiated and exclusive offering for the company’s elite aesthetic partners and their patients.

Therapeutics 

Seeking Innovation to Multiple Indications

Revance’s therapeutics programs will bring innovation to multiple indications, with a current focus in muscle movement disorders including some debilitating conditions.

revance

Revance by
the numbers

0
Year Founded

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

RVNC
Publicly Traded on NASDAQ

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

0
Years Invested in R&D

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

0
Divisions:
Aesthetics + Therapeutics

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

~
0
Employees

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

$
0
M
2021 Total Revenue

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

0
+
Elite Aesthetic Partners

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

5,00 0
+
Injectors Trained to Date

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products

revance timeline

2002-2022

Scroll to see Timeline

2002

Essentia Biosystems founded in a Silicon Valley think tank in Palo Alto, CA by Dan Browne, Micheal Dake, M.D. and Jacob Waugh, M.D.
Essentia Biosystems Founders
Peptide
Founded to explore the potential use of peptides in the delivery of macromolecules for therapeutic diagnostic purposes connecting biologics and peptides such as immune modulators, insulin and botulinum toxins

2004

Moved to lab in garage in Mountain View, CA
New Lab Location
New Revance Logo

2006

Renamed Revance Therapeutics, by then board member, Rowland Hansen, one of Bill Gates’ early hires who named Microsoft Windows

2007

Initiated clinical development for RT001, topical botulinum toxin type A gel, in lateral canthal lines
Crows Feet
Biotech Bay

2008

Moved into Newark Headquarters in Biotech Bay
Initiated clinical development for RT001 topical formulation for axillary hyperhidrosis
Water Drops
Inside Manufacturing Facility

2010

Manufacturing facility opened in Newark, CA

2012

Initiated clinical development for RT002 with first human subjects in Mexico
Mexico
Cervial Dystonia and Plantar Fascitis Icons

2014

Initiated clinical development for DaxibotulinumtoxinA for Injection in glabellar lines
RVNC NASDAQ IPO
Time Square - Revance
Cervial Dystonia and Plantar Fascitis Icons
Initiated clinical development for DaxibotulinumtoxinA for Injection in cervical dystonia and plantar fasciitis

2017

SAKURA 3 Logo
Positive results reported in SAKURA Phase 3 program in glabellar lines. Completion of 1st pivotal program for Revance
sakura leaves
Mylan Logo

2018

Global collaboration and license agreement with Mylan for the development and commercialization of a proposed biosimilar to BOTOX®
*BOTOX® is a registered trademark of Allergan, Inc
FOSUN Pharma Logo
Agreement with Fosun Pharma in China in aesthetics and therapeutics

2019

Mark J. Foley appointed President and CEO
Mark Foley
Forehead Injections Icons
BLA submitted for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines
Exclusive rights to the RHA® Collection of dermal fillers in the U.S.
RHA collection Logo
Forehead and Crows Feet injection icons

2020

Positive results in two Phase 2a studies, forehead lines and lateral canthal lines
Acquired HintMD, first fintech platform in aesthetics
HintMD
Viatris
Advanced development program for biosimilar to BOTOX® with Viatris (previously Mylan)
*BOTOX® is a registered trademark of Allergan, Inc
Launch of Revance Aesthetics
Revance Aesthetics
Revance Aesthetics Conference
Hired first Revance Aesthetics sales force
Commerical Launch of RHA® 2, 3 and 4.
RHA® 2, 3, and 4
ASPEN-1
Positive results in ASPEN-1 Phase 3 trial in cervical dystonia

2021

Expanded National Footprint
Revance offices across America
New Revance Office
Revance Global Headquarters and Experience Center moved to Nashville, TN
Positive results in JUNIPER Phase 2 trial in upper limb spasticity
Juniper
China
First patient enrolled for DaxibotulinumtoxinA for Injection in glabellar lines and cervical dystonia in China
Relational Commerce Platform Launched
OPUL

Our products

Revance is setting the new standard in the aesthetic and therapeutics indications

Our prestige facial aesthetics portfolio, including DaxibotulinumtoxinA for Injection the RHA® Collection of dermal fillers, and the OPUL financial technology (fintech) platform, offer a compelling value proposition and an elevated experience for physicians and patients. Revance’s innovative therapeutics program is currently focused on muscle movement disorders including two debilitating conditions, cervical dystonia and upper limb spasticity.

INDICATION
DaxibotulinumtoxinA for Injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DaxibotulinumtoxinA for Injection and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY™ is not approved for the treatment of spasticity or any conditions other than glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications
DaxibotulinumtoxinA for Injection contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DaxibotulinumtoxinA for Injection are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DaxibotulinumtoxinA for Injection and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DaxibotulinumtoxinA for Injection may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DaxibotulinumtoxinA for Injection is unknown.

Use in Specific Populations
DaxibotulinumtoxinA for Injection is not recommended for use in children or pregnant women.

Please see DaxibotulinumtoxinA for Injection full Prescribing Information, including Boxed Warning and Medication Guide.